BioSpace News Archive

Launch of company’s Site Advisory Council and meeting with Patient Advisory Council held on International Clinical Trials Day 2020; address clinical trial challenges during pandemic

Arena Pharmaceuticals, Inc. announced that on May 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 113,175 shares of its common stock to 13 new employees and 16,510 inducement restricted stock units to ten new employees.

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that the Company will present at the Bernstein 36th Annual Strategic Decisions Conference on Wednesday, May 27, 2020 at 8:00 a.m. ET.

MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced financial results for the first quarter ended March 31, 2020 and provided business and financial updates related to the COVID-19 pandemic.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will report its first quarter 2020 financial results on Wednesday, May 27, 2020.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces its rebranding.

AlivaMab Discovery Services, LLC, a leader in comprehensive, integrated solutions for antibody drug discovery, announced the planned transition of its chief executive officer from Larry Green, PhD, to Justin Mika, effective May 6, 2020.

Aldeyra Therapeutics, Inc. announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibitor in development for COVID-19 and other inflammatory diseases.

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it and its subsidiaries have entered into a $30 million debt facility with Avenue Venture Opportunities Fund, L.P. (Avenue), a fund within the Avenue Capital Group, and its affiliates. “This new debt fa

Trial conducted at Columbia University will investigate potential of chloroquine phosphate to prevent symptomatic SARS-CoV-2 infections